Search | Clinical Trials Finder

Conditions: Dyslipidaemias, Dyslipidemias
Interventions: 10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function; Drug · Device · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypercholesterolemia
Interventions: AVE5530, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Dyslipidemia
Interventions: BMS-823778, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Little Rock, Arkansas • Lenexa, Kansas • Cincinnati, Ohio + 3 more

Conditions: Atherosclerosis
Interventions: MLDL1278A, placebo, statin, stable dose; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 22
States / cities: Torrance, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 15 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Alirocumab, Placebo, LMT; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years and older
Enrollment: 18,924 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 273
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 218 more

Conditions: Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions: CAT-2003, Placebo, Statin; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 13
States / cities: Muscle Shoals, Alabama • Los Angeles, California • Jacksonville, Florida + 7 more

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 29
States / cities: Encino, California • Fresno, California • Oakland, California + 25 more

Conditions: Hypercholesterolemia
Interventions: Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 115
States / cities: Huntsville, Alabama • Gilbert, Arizona • Sierra Vista, Arizona + 90 more

Conditions: Hypercholesterolemia
Interventions: LGT209, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Miami Gardens, Florida • Fargo, North Dakota

Conditions: Hypercholesterolemia
Interventions: Placebo (for alirocumab), Alirocumab, Statin; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 49
States / cities: Chandler, Arizona • Goodyear, Arizona • Carmichael, California + 46 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Hypercholesterolemia
Interventions: Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 76
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and stable statin therapy, Stable statin therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 13
States / cities: Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more

Conditions: Dyslipidemia
Interventions: Evolocumab, Placebo, Background Statin Therapy; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 134
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 123 more

Conditions: Hypercholesterolemia
Interventions: Evinacumab, Matching placebo, Background Lipid Modifying Therapy (LMT); Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 23
States / cities: Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, Ezetimibe, Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more

Conditions: Dyslipidemia
Interventions: Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 57
States / cities: Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more

Conditions: Hypercholesterolemia, LDL Cholesterol
Interventions: LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more

Conditions: Hypercholesterolemia
Interventions: colesevelam HCl, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • New Hyde Park, New York + 5 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Lipid-Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 44
States / cities: Huntsville, Alabama • Tempe, Arizona • Bell Gardens, California + 39 more

Search by objective public record fields.

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

Open Label Study of Long Term Safety Evaluation of Alirocumab